Wagner Ernst, Culmsee Carsten, Boeckle Sabine
Pharmaceutical Biology ‐ Biotechnology, Department of Pharmacy, Ludwig‐Maximilians‐Universitaet Muenchen, Butenandtstr. 5‐13, D‐81377 Munich, Germany.
Adv Genet. 2005;53PA:333-354. doi: 10.1016/S0065-2660(05)53013-X.
Dominating issues in gene vector optimization are specific in recognizing the target cells and exploiting the proper intracellular trafficking routes. Any progress in this area will result in improved specific gene transfer, reduce the required therapeutic vector doses and, in consequence, lower the overall toxicity to the host. To provide polyplexes with the ability to distinguish between non-target and target cells, cell-binding ligands have been incorporated which recognize target-specific cellular receptors. In addition, polyplex domains with unspecific binding capacity (such as surface charges) have to be shielded or removed. Cell-binding ligands can be small molecules, vitamins, carbohydrates, peptides or proteins such as growth factors or antibodies. Such ligands have been incorporated into polyplexes after chemical conjugation to cationic polymers. The choice of the ligand and physical properties of the DNA formulation strongly influence extracellular routing (circulation in blood, tissue distribution), uptake and intracellular delivery of polyplexes. Recent efforts are discussed that aim at the development of polyplexes into virus-like supramolecular complexes; such particles should undergo structural changes compatible with extracellular and intracellular targeting.
基因载体优化中的主要问题在于特异性识别靶细胞并利用适当的细胞内运输途径。该领域的任何进展都将带来更高效的特异性基因传递,减少所需的治疗性载体剂量,从而降低对宿主的总体毒性。为了使多聚体能够区分非靶细胞和靶细胞,人们引入了能够识别靶细胞特异性细胞受体的细胞结合配体。此外,具有非特异性结合能力的多聚体结构域(如表面电荷)必须被屏蔽或去除。细胞结合配体可以是小分子、维生素、碳水化合物、肽或蛋白质,如生长因子或抗体。这些配体在与阳离子聚合物进行化学偶联后被整合到多聚体中。配体的选择和DNA制剂的物理性质强烈影响多聚体的细胞外运输(血液中的循环、组织分布)、摄取和细胞内递送。本文讨论了近期旨在将多聚体发展为病毒样超分子复合物的研究工作;此类颗粒应经历与细胞外和细胞内靶向兼容的结构变化。